# Aratana Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/aratana-therapeutics

- Industry: Pharmaceuticals
- Headquarters: Leawood, US
- Website: www.aratana.com
- Total disclosed funding: $56M
- Latest round: Series C (Jan 31, 2013)
- Investors on record: 8

## About

Established in 2010 and based in Kansas, US, Aratana Therapeutics, Inc. operates as a developer of therapeutics for dogs and cats. The company offers Galliprant® which used for pain relief to early diagnosed stages of Osteoarthritis, ENTYCE® which is used in restoring appetite and NOCITA®, an injectible post-surgical pain relief.

## Funding rounds

- Series C, Jan 31, 2013, $12M — Ewing Marion Kauffman Foundation, MPM BioImpact, Midwest Venture Alliance, Kansas Bioscience Authority, Middleland Capital
- Series C, Dec 28, 2012, $9.1M — MPM BioImpact
- Series B, Dec 7, 2011, $15M — Avalon Ventures, Ewing Marion Kauffman Foundation, Cultivian Sandbox Ventures, MPM BioImpact, Kansas Technology Enterprise Corporation
- Series A, Dec 27, 2010, $20M — Avalon Ventures, MPM BioImpact

## Investors

- Avalon Ventures (https://capitalatlas.ai/funds/avalon-ventures) — Series A, Series B
- MPM BioImpact (https://capitalatlas.ai/funds/mpm-bioimpact) — Series A, Series B, Series C
- Ewing Marion Kauffman Foundation — Series B, Series C
- Cultivian Sandbox Ventures (https://capitalatlas.ai/funds/cultivian-sandbox-ventures) — Series B
- Kansas Technology Enterprise Corporation — Series B
- Midwest Venture Alliance — Series C
- Kansas Bioscience Authority — Series C
- Middleland Capital — Series C